Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug
Staphylococcal enterotoxin C2 (SEC2) is a classical superantigen (SAg), which can tremendously activate T lymphocytes at very low dosage, thus exerting its powerful antitumor activity. As an intravenous protein drug and a bacterial toxin, SEC2 has some limitations including poor patient compliance a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-06-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6651/8/6/185 |
| _version_ | 1811298041082150912 |
|---|---|
| author | Wenbin Zhao Yangyang Li Wenhui Liu Ding Ding Yingchun Xu Liqiang Pan Shuqing Chen |
| author_facet | Wenbin Zhao Yangyang Li Wenhui Liu Ding Ding Yingchun Xu Liqiang Pan Shuqing Chen |
| author_sort | Wenbin Zhao |
| collection | DOAJ |
| description | Staphylococcal enterotoxin C2 (SEC2) is a classical superantigen (SAg), which can tremendously activate T lymphocytes at very low dosage, thus exerting its powerful antitumor activity. As an intravenous protein drug and a bacterial toxin, SEC2 has some limitations including poor patient compliance and toxic side effects. In this research, we devoted our attention to studying the antitumor activity and toxicity of SEC2 as a potential oral administration protein drug. We proved that His-tagged SEC2 (SEC2-His) could undergo facilitated transcytosis on human colon adenocarcinoma (Caco-2) cells and SEC2-His was detected in the blood of rats after oral administration. Furthermore, oral SEC2-His caused massive cytokine release and immune cell enrichment around tumor tissue, leading to inhibition of tumor growth in vivo. Meanwhile, although SEC2-His was dosed up to 32 mg/kg in mice, no significant toxicity was observed. These data showed that SEC2 can cross the intestinal epithelium in an immunologically integral form, maintaining antitumor activity but with reduced systemic toxicity. Therefore, these results may have implications for developing SEC2 as an oral administration protein drug. |
| first_indexed | 2024-04-13T06:13:51Z |
| format | Article |
| id | doaj.art-d8118072107d462da0656c59de17d64b |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-04-13T06:13:51Z |
| publishDate | 2016-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-d8118072107d462da0656c59de17d64b2022-12-22T02:58:56ZengMDPI AGToxins2072-66512016-06-018618510.3390/toxins8060185toxins8060185Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein DrugWenbin Zhao0Yangyang Li1Wenhui Liu2Ding Ding3Yingchun Xu4Liqiang Pan5Shuqing Chen6College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, ChinaCollege of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, ChinaCollege of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, ChinaHisun Pharma (Hangzhou). CO., LTD., Xialian Village, Xukou Town, Fuyang, Hangzhou 311404, ChinaCollege of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, ChinaCollege of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, ChinaCollege of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, ChinaStaphylococcal enterotoxin C2 (SEC2) is a classical superantigen (SAg), which can tremendously activate T lymphocytes at very low dosage, thus exerting its powerful antitumor activity. As an intravenous protein drug and a bacterial toxin, SEC2 has some limitations including poor patient compliance and toxic side effects. In this research, we devoted our attention to studying the antitumor activity and toxicity of SEC2 as a potential oral administration protein drug. We proved that His-tagged SEC2 (SEC2-His) could undergo facilitated transcytosis on human colon adenocarcinoma (Caco-2) cells and SEC2-His was detected in the blood of rats after oral administration. Furthermore, oral SEC2-His caused massive cytokine release and immune cell enrichment around tumor tissue, leading to inhibition of tumor growth in vivo. Meanwhile, although SEC2-His was dosed up to 32 mg/kg in mice, no significant toxicity was observed. These data showed that SEC2 can cross the intestinal epithelium in an immunologically integral form, maintaining antitumor activity but with reduced systemic toxicity. Therefore, these results may have implications for developing SEC2 as an oral administration protein drug.http://www.mdpi.com/2072-6651/8/6/185staphylococcal enterotoxin C2superantigenoral administrationantitumor activitytoxicity |
| spellingShingle | Wenbin Zhao Yangyang Li Wenhui Liu Ding Ding Yingchun Xu Liqiang Pan Shuqing Chen Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug Toxins staphylococcal enterotoxin C2 superantigen oral administration antitumor activity toxicity |
| title | Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug |
| title_full | Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug |
| title_fullStr | Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug |
| title_full_unstemmed | Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug |
| title_short | Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug |
| title_sort | transcytosis antitumor activity and toxicity of staphylococcal enterotoxin c2 as an oral administration protein drug |
| topic | staphylococcal enterotoxin C2 superantigen oral administration antitumor activity toxicity |
| url | http://www.mdpi.com/2072-6651/8/6/185 |
| work_keys_str_mv | AT wenbinzhao transcytosisantitumoractivityandtoxicityofstaphylococcalenterotoxinc2asanoraladministrationproteindrug AT yangyangli transcytosisantitumoractivityandtoxicityofstaphylococcalenterotoxinc2asanoraladministrationproteindrug AT wenhuiliu transcytosisantitumoractivityandtoxicityofstaphylococcalenterotoxinc2asanoraladministrationproteindrug AT dingding transcytosisantitumoractivityandtoxicityofstaphylococcalenterotoxinc2asanoraladministrationproteindrug AT yingchunxu transcytosisantitumoractivityandtoxicityofstaphylococcalenterotoxinc2asanoraladministrationproteindrug AT liqiangpan transcytosisantitumoractivityandtoxicityofstaphylococcalenterotoxinc2asanoraladministrationproteindrug AT shuqingchen transcytosisantitumoractivityandtoxicityofstaphylococcalenterotoxinc2asanoraladministrationproteindrug |